PE20040562A1 - Vacunas que comprenden mezclas de cepas meningococicas multivalentes - Google Patents

Vacunas que comprenden mezclas de cepas meningococicas multivalentes

Info

Publication number
PE20040562A1
PE20040562A1 PE2003000583A PE2003000583A PE20040562A1 PE 20040562 A1 PE20040562 A1 PE 20040562A1 PE 2003000583 A PE2003000583 A PE 2003000583A PE 2003000583 A PE2003000583 A PE 2003000583A PE 20040562 A1 PE20040562 A1 PE 20040562A1
Authority
PE
Peru
Prior art keywords
heterological
meningococcal
multivalent meningococcal
meningococcal strains
deficient
Prior art date
Application number
PE2003000583A
Other languages
English (en)
Spanish (es)
Inventor
Morales Ramon Faustino Barbera
Alvarez Francisco Jesus Dominguez
Pierre Michel Desmons
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Inst Finlay Ct De Investigacion Produccion De Sueros Y Vacunas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Inst Finlay Ct De Investigacion Produccion De Sueros Y Vacunas filed Critical Glaxosmithkline Biolog Sa
Publication of PE20040562A1 publication Critical patent/PE20040562A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2003000583A 2002-06-13 2003-06-11 Vacunas que comprenden mezclas de cepas meningococicas multivalentes PE20040562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation

Publications (1)

Publication Number Publication Date
PE20040562A1 true PE20040562A1 (es) 2004-10-19

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000583A PE20040562A1 (es) 2002-06-13 2003-06-11 Vacunas que comprenden mezclas de cepas meningococicas multivalentes

Country Status (20)

Country Link
US (1) US20060110412A1 (enExample)
EP (1) EP1565211A2 (enExample)
JP (1) JP2005531614A (enExample)
KR (1) KR20050049431A (enExample)
CN (1) CN100387298C (enExample)
AR (1) AR040204A1 (enExample)
AU (1) AU2003236734A1 (enExample)
BR (1) BR0311777A (enExample)
CA (1) CA2488782A1 (enExample)
CL (1) CL2003001192A1 (enExample)
CU (1) CU23552A1 (enExample)
GB (1) GB0213622D0 (enExample)
MX (1) MXPA04012568A (enExample)
NO (1) NO20050132L (enExample)
NZ (1) NZ560766A (enExample)
PE (1) PE20040562A1 (enExample)
RU (1) RU2005100509A (enExample)
UY (1) UY27843A1 (enExample)
WO (1) WO2003105890A2 (enExample)
ZA (1) ZA200409547B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
BRPI0607374B8 (pt) 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
CA2808919C (en) * 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
CN105044337A (zh) * 2008-02-01 2015-11-11 圣诺菲·帕斯图尔有限公司 用于诊断肺炎链球菌的试验
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
EP2486940B1 (en) * 2009-10-08 2017-10-04 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
JP5894083B2 (ja) * 2009-12-22 2016-03-23 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
EP2549990A1 (en) 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2011127302A2 (en) * 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
CA3166272A1 (en) * 2020-10-23 2022-04-28 Omvax, Inc. Compositions and methods for vaccination against neisseria gonorrhoeae
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
KR20030024811A (ko) * 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신

Also Published As

Publication number Publication date
KR20050049431A (ko) 2005-05-25
MXPA04012568A (es) 2005-09-21
US20060110412A1 (en) 2006-05-25
WO2003105890A3 (en) 2004-03-25
CN1668329A (zh) 2005-09-14
NO20050132D0 (no) 2005-01-11
CN100387298C (zh) 2008-05-14
CU23552A1 (es) 2010-07-20
AU2003236734A1 (en) 2003-12-31
NZ560766A (en) 2009-09-25
GB0213622D0 (en) 2002-07-24
ZA200409547B (en) 2006-07-26
CA2488782A1 (en) 2003-12-24
BR0311777A (pt) 2005-03-29
CL2003001192A1 (es) 2005-01-07
RU2005100509A (ru) 2006-06-10
AR040204A1 (es) 2005-03-16
UY27843A1 (es) 2003-12-31
NO20050132L (no) 2005-02-11
WO2003105890A2 (en) 2003-12-24
JP2005531614A (ja) 2005-10-20
EP1565211A2 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
PE20040562A1 (es) Vacunas que comprenden mezclas de cepas meningococicas multivalentes
FR13C0040I2 (fr) Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
AR061333A1 (es) Composiciones de vacuna de la neisseria
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR0015961A (pt) Antìgeno de neisseria de 85kda
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
DK117491D0 (da) Vaccine imod meningococcussygdomme, deri indgaaende komponenter, disses anvendelse og rekombinanter, som eksprimerer dem
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
BRPI0410684A (pt) uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
BR0113822A (pt) Vacina
MY169275A (en) Method of immunization against the four serotypes of dengue
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
CY1106771T1 (el) Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2
AR035652A1 (es) Una composicion nutricional, util para combatir la infeccion en el tracto gastrointestinal causada por organismos tipo helicobacter, el uso de dicha composicion para la preparacion de medicamentos, o productos alimenticios y el procedimiento para preparar dicha composicion
ECSP044986A (es) Composicion farmaceutica que comprende lumiracoxib
NO20031963D0 (no) Fremgangsmåter og preparater for behandling av sykdommer i öyet
DE602004020488D1 (de) Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BRPI0412506A (pt) células autólogas que induzem à autotoleráncia de origem monocìtica e seu uso em preparações farmacêuticos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed